Document Detail


Thrombolytic therapy in acute myocardial infarction.
MedLine Citation:
PMID:  2524993     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Early thrombolytic therapy has been shown to reduce hospital mortality after myocardial infarction by 20-50%. This is achieved through reperfusion of the ischemic myocardium, which leads to limitation of infarct size by 15-30% and preservation of regional and global left ventricular function. Thrombolysis and reperfusion can be achieved by intravenous administration of streptokinase, urokinase, APSAC, or rt-PA, or by intracoronary administration of streptokinase or urokinase. Thrombolytic therapy is most effective in patients with extensive myocardial ischemia (large infarction) treated early after the onset of symptoms, but also patients with smaller infarcts may benefit from the therapy. It is uncertain whether treatment later than six hours after the onset of symptoms is beneficial, and if so, in which patients. Thrombolytic therapy leads to bleeding complications in a minority of patients. The risk of intracranial bleeding is approximately 0.5%. However, in several large trials the rate of cerebrovascular accidents (bleeding plus embolism) was not higher after thrombolytic therapy with streptokinase or rt-PA than after placebo. In order to prevent rethrombosis, additional treatment with acetyl salicylic acid and heparin is recommended. Nitrates and antiarrhythmic drugs are not recommended as routine practice. Immediate PTCA does not improve patient outcome. At present angiography and subsequent angioplasty or bypass surgery is recommended in patients with recurrent ischemia (spontaneous or upon exercise) after the infarct.
Authors:
M L Simoons
Related Documents :
2182243 - Expanding indications for the use of thrombolytic agents in acute myocardial infarction.
12225723 - Marked bradykinin-induced tissue plasminogen activator release in patients with heart f...
10028543 - Early postoperative complications after coronary artery bypass grafting at the cardiova...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annual review of medicine     Volume:  40     ISSN:  0066-4219     ISO Abbreviation:  Annu. Rev. Med.     Publication Date:  1989  
Date Detail:
Created Date:  1989-06-27     Completed Date:  1989-06-27     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  2985151R     Medline TA:  Annu Rev Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  181-200     Citation Subset:  IM    
Affiliation:
Thoraxcenter, University Hospital Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon / economics
Coronary Artery Bypass / economics
Cost-Benefit Analysis
Fibrinolytic Agents / adverse effects,  therapeutic use*
Humans
Myocardial Infarction / mortality,  therapy*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A controlled clinical trial of baclofen as protective therapy in early Huntington's disease.
Next Document:  Sarcoidosis.